CORDIS
EU research results

CORDIS

English EN

New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier

Project information

Grant agreement ID: 281035

Status

Closed project

  • Start date

    1 May 2012

  • End date

    30 April 2017

Funded under:

FP7-NMP

  • Overall budget:

    € 10 748 102,64

  • EU contribution

    € 8 000 000

Coordinated by:

UNIVERSIDAD DE SANTIAGO DE COMPOSTELA

Spain

Objective

Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies have failed to deliver on their expectations because they cannot be administered in the fashion which is most cost efficient and has the highest patient compliance: the oral route. The availability of an oral form of administration could lead to a great improvement of classical therapies and it would also make a high number of new therapies feasible. To make this happen, the final objective of Trans-INT is to design nanocarriers specifically adapted to deal with the gastrointestinal ecosystem and use them for the development of new oral nanomedicines for diseases with high socioeconomic impact (i.e. metabolic diseases, pain medication).

The concept behind TRANS-INT is the rational design of oral nanomedicines based on safety, mechanistic, bioengineering (multifunctional nanocarriers: high payload, drug protection, efficient drug transport, controlled release) and pharmaceutical technology criteria (scalable technology and stability). The project will start with nanocarrier platforms on which the partners have IPR and freedom to operate: nanocapsules, nanoparticles, micelles made of combinations of lipids, polypeptides and polysaccharides, continue with the optimization and redefinition of selected nanocarriers. It is expected to end with (i) at least one oral nanocarrier prototype with a comprehensive GLP-tox package, which could be applied for the delivery of a high number of peptide molecules, (ii) at least one nanomedicine fulfilling target product profile criteria, with a comprehensive preclinical evaluation package, (iii) substantial integrative knowledge on the feasibility and potential of oral nanocarriers and nanopharmaceuticals. TRANS-INT is expected to have a great impact no only from the new therapies/patients perspective but also from the innovation and EU industrial development perspective.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSIDAD DE SANTIAGO DE COMPOSTELA

Address

Colexio De San Xerome Praza Do Obradoiro S/N
15782 Santiago De Compostela

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 665 013,76

Administrative Contact

Martin Cacheiro Martinez (Mr.)

Participants (17)

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 654 159,40

UNIVERSITE CATHOLIQUE DE LOUVAIN

Belgium

EU Contribution

€ 506 920

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 355 755,23

UCL Elizabeth Garrett Anderson Institute for Women’s Health

United Kingdom

EU Contribution

€ 699 576

ADVANCELL ADVANCED IN VITRO CELL TECHNOLOGIES S.A

Spain

VENETO NANOTECH SOCIETA CONSORTILEPER AZIONI

Italy

EU Contribution

€ 117 477,29

SIGMOID PHARMA LIMITED

Ireland

EU Contribution

€ 390 900

UNIVERSITE D'ANGERS

France

EU Contribution

€ 558 305,22

MEDIZINISCHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 434 880

FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)

Spain

EU Contribution

€ 302 040

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 449 436,40

Participant Legal name Istituto Oncologico Veneto IRCCS

Italy

EU Contribution

€ 301 400

SEROSCIENCE LTD

Hungary

EU Contribution

€ 346 320

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

France

EU Contribution

€ 616 154

F. HOFFMANN-LA ROCHE AG

Switzerland

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK

Ireland

EU Contribution

€ 459 100

ECAMRICERT SRL

Italy

EU Contribution

€ 142 562,70

Project information

Grant agreement ID: 281035

Status

Closed project

  • Start date

    1 May 2012

  • End date

    30 April 2017

Funded under:

FP7-NMP

  • Overall budget:

    € 10 748 102,64

  • EU contribution

    € 8 000 000

Coordinated by:

UNIVERSIDAD DE SANTIAGO DE COMPOSTELA

Spain

This project is featured in...